Medical treatment technology, Diagnostic technology

## Life Sciences

# Establishment of Support Business for Cell Therapy

Keyword: Regeneration of skin, Spread of regenerative medicine industry

Organizations Involved

○ Minoru Ueda DDS, PhD, Professor, Graduate School of Medicine, Nagoya University

○ Akio Hayashi, CEO, TES (Tissue Engineering Support) Co., Ltd.

Prof. Ueda

## 【Abstract】

The Dr. Ueda’s laboratory of Nagoya University pulled the area of regenerative medicine for skin and bone regeneration in Japan. However, for practical use of the regenerative therapy, there is various bottleneck such as huge costs for a clinical trial. Therefore, the TES Holding Co., Ltd. regarded that the technology of regeneration therapy is assets of citizen, established regenerative medical support business for the people. The treatment system, which was the cell therapy for skin collapse lesion, was constructed.

## [Summary of the technology transfer]

## Technological Impact

The Conventional treatment for a skin collapse-related lesion is injection of collagen or hyaluronic acid gel. However, these treatments have a short effect duration (2-4 months), and they may induce infection or allergic reactions. In contrast, the treatment uses for autologous cell is safety and it has long effect duration (more than 3 years). In addition, we succeeded in establishment of an effective and less invasive treatment to use the fibroblast which from oral mucosa.

Hayashi CEO

## ● Social Impact

## ●Special Features of the Collaboration

If these technology spread to a general medical institution, the patient can choose alternative treatment and people can be received a benefit of regenerative therapy immediately.

Currently, we are developing treatment protocol, clinical apparatuses, management system to perform safety / efficiency / low-priced treatment. These therapeutic strategies contribute to spread the novel regenerative medical technology.

O'Market Size of Regenerative Treatment for Skin

2010: 100,000,000 ~ 200,000,000 yen

2020: 500,000,000 ~ 1,000,000,000 yen

2010: 1,000,000,000 ~ 2,000,000,000 yen

2020: 10,000,000,000 ~ 20,000,000,000 yen

## Project Background

There was many barrier for practical use and spreading of regenerative medicine with evidence in availability and safety. The TES Holding Co., Ltd. constructed an early practical use system by a free medical care model under the medical practitioners law.

## Funding History

1. A grant by Ministry of Education, Culture, Sports, Science and Technology

2. The TES Holdings Co., Ltd.

“Development of clinical application for cell therapy using cultured cells”

## I ntellectual property protection

Application: Domestic 2, International 1 Improving material for skin and its producing method PCT/JP2006/312871

Treatment for skin concaved deformity using cultured autologous gingival fibroblasts

Harvesting a oral tissue and taking blood from the patient. Cell suspension is injected into the concaved lesion, such as wrinkles followed by fibroblasts culture, expansion in cell processing center.

fibroblast

Because of minimum invasive procedure, and theoretically no risk of allergic reaction and infection, our method is extremely safe comparing to conventional filler treatment. [Case] concaved scar in right forehead

(left) before treatment, (right) 1 year after treatment, scar is improved.

## Turning point in the Project

OSpreading the concept of regenerative medicine and raising its recognition OPromotion of efficiency of a cell preparation process and reduction of its expense

OExplanation of the patent reliability and a new technology to a company